274. 骨形成不全症 Osteogenesis Imperfecta Clinical trials / Disease details
臨床試験数 : 87 / 薬物数 : 103 - (DrugBank : 20) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 76
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-000745-21-BE (EUCTR) | 10/12/2012 | 18/09/2012 | An international, multicenter, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta | An international, multicenter, open-label, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta - SHC - INFOI | Children suffering from severe Osteogenesis Imperfecta MedDRA version: 14.1;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: ACLASTA Product Name: zoledronic acid INN or Proposed INN: RITUXIMAB | Schriners Hospitals for Children | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 15 | United States;Canada;Belgium | |||
| 2 | EUCTR2011-002811-27-DK (EUCTR) | 07/11/2011 | 04/11/2011 | The Effect of Treatment with PTH and Zoledronic acid in Patients with Osteogenesis Imperfecta | The Effect of Treatment with PTH and Zoledronic acid in Patients with Osteogenesis Imperfecta - OI-treatment | Osteogenesis imperfecta;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Forsteo Product Code: H05AA02 Trade Name: Aclasta | Bente Langdahl, consultant, ass. professor, PhD, DMSc | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | Denmark |